Edgewise Therapeutics, Inc. Income (Loss) from Continuing Operations, Per Basic Share
Edgewise Therapeutics, Inc. (EWTX) reported Income (Loss) from Continuing Operations, Per Basic Share of -$0.39 per share for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsPerBasicShare · last filed 2025-11-06
- Edgewise Therapeutics, Inc. income (loss) from continuing operations, per basic share for the quarter ending 2025-09-30 was -$0.39.
- Edgewise Therapeutics, Inc. income (loss) from continuing operations, per basic share for the quarter ending 2025-06-30 was -$0.34.
- Edgewise Therapeutics, Inc. income (loss) from continuing operations, per basic share for the quarter ending 2025-03-31 was -$0.43.
- Edgewise Therapeutics, Inc. income (loss) from continuing operations, per basic share for the quarter ending 2024-09-30 was -$0.36.
- Edgewise Therapeutics, Inc. income (loss) from continuing operations, per basic share for fiscal 2024 was -$1.45.
- Edgewise Therapeutics, Inc. income (loss) from continuing operations, per basic share for fiscal 2023 was -$1.57.
- Edgewise Therapeutics, Inc. income (loss) from continuing operations, per basic share for fiscal 2022 was -$1.26.
- Edgewise Therapeutics, Inc. income (loss) from continuing operations, per basic share for fiscal 2021 was -$1.14.
| Period end | Income (Loss) from Continuing Operations, Per Basic Share 3 month | Income (Loss) from Continuing Operations, Per Basic Share 6 month | Income (Loss) from Continuing Operations, Per Basic Share 9 month | Income (Loss) from Continuing Operations, Per Basic Share 12 month |
|---|---|---|---|---|
| 2025-09-30 | -$0.39 10-Q · filed 2025-11-06 | -$1.15 10-Q · filed 2025-11-06 | ||
| 2025-06-30 | -$0.34 10-Q · filed 2025-08-07 | -$0.77 10-Q · filed 2025-08-07 | ||
| 2025-03-31 | -$0.43 10-Q · filed 2025-05-08 | |||
| 2024-12-31 | -$1.45 10-K · filed 2025-03-03 | |||
| 2024-09-30 | -$0.36 10-Q · filed 2025-11-06 | -$1.03 10-Q · filed 2025-11-06 | ||
| 2024-06-30 | -$0.34 10-Q · filed 2025-08-07 | -$0.66 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | -$0.33 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | -$1.57 10-K · filed 2025-03-03 | |||
| 2023-09-30 | -$0.41 10-Q · filed 2024-11-07 | -$1.10 10-Q · filed 2024-11-07 | ||
| 2023-06-30 | -$0.34 10-Q · filed 2024-08-08 | -$0.70 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | -$0.36 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | -$1.26 10-K · filed 2024-02-22 | |||
| 2022-09-30 | -$0.34 10-Q · filed 2023-11-09 | -$0.96 10-Q · filed 2023-11-09 | ||
| 2022-06-30 | -$0.32 10-Q · filed 2023-08-10 | -$0.62 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | -$0.30 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | -$1.14 10-K · filed 2023-02-23 | |||
| 2021-09-30 | -$0.26 10-Q · filed 2022-11-03 | -$0.90 10-Q · filed 2022-11-03 | ||
| 2021-06-30 | -$0.21 10-Q · filed 2022-08-04 | -$0.67 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | -$4.37 10-Q · filed 2022-05-11 | |||
| 2020-12-31 | -$23.17 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 |